Contact Centers For Pharma Market Report 2026

Contact Centers For Pharma Market Overview

• Contact Centers For Pharma market size has reached to $2.95 billion in 2025 • Expected to grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.6% • Growth Driver: Expansion Of Clinical Trials Driving The Contact Centers For Pharma Market Growth Due To Increasing Demand For Efficient Trial Communication And Coordination • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Contact Centers For Pharma Market?

Contact centers for pharma refer to specialized communication and support service operations that manage inbound and outbound interactions between pharmaceutical organizations and healthcare stakeholders, including handling medical inquiries, patient support services, adverse event reporting, appointment scheduling assistance, and product-related information dissemination. These contact centers are designed to ensure regulatory compliance, accurate information handling, and consistent service quality while supporting pharmacovigilance and patient engagement activities. The main components of contact centers for pharma include software and services. Software refers to digital platforms used to manage communication, case handling, and customer interaction workflows in pharmaceutical contact center operations. These systems are used across functions including customer support, medical information, adverse event reporting, patient adherence, sales support, and other functions and are designed for enterprise sizes such as large enterprises and small and medium enterprises. They are deployed through on premises and Cloud-Based models and are utilized by end users including pharmaceutical companies, contract research organizations, healthcare providers, and others.

What Is The Contact Centers For Pharma Market Growth Forecast?

The contact centers for pharma market size is expected to see rapid growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing deployment of AI enabled conversational agents and virtual assistants, expansion of cloud based scalable pharma contact center infrastructure, rising focus on patient centric care and engagement models, growth in real time pharmacovigilance and safety monitoring requirements, increasing integration of advanced analytics in pharma communication workflows. Major trends in the forecast period include AI powered omnichannel pharma contact center automation and intelligent routing systems, cloud based patient engagement and support communication platforms, integrated pharmacovigilance reporting and real time safety monitoring workflows, data driven customer experience personalization in pharmaceutical communication services, increasing adoption of virtual medical information and remote patient support services.

Global Contact Centers For Pharma Market Segmentation

1) By Component: Software, Services 2) By Function: Customer Support, Medical Information, Adverse Event Reporting, Patient Adherence, Sales Support, Other Function 3) By Enterprise Size: Large Enterprises, Small And Medium Enterprises 4) By Deployment Mode: On Premises, Cloud-Based 5) By End User: Pharmaceutical Companies, Contract Research Organizations, Healthcare Providers, Other End Users Subsegments: 1) By Software: Omnichannel Contact Center Software, Customer Relationship Management Integration Software, Interactive Voice Response Software, Workforce Management Software, Analytics And Reporting Software 2) By Services: Implementation And Integration Services, Consulting And Advisory Services, Managed Contact Center Services, Training And Support Services, Maintenance And Optimization Services

What Are The Drivers Of The Contact Centers For Pharma Market?

The expansion of clinical trials is expected to propel the growth of the contact centers for pharma market going forward. Clinical trials refer to carefully designed research studies conducted on human participants to evaluate the safety, effectiveness, and side effects of new medical treatments, drugs, or medical devices before they are approved for public use. Clinical trials are growing due to increasing demand for new and more effective treatments for chronic and complex diseases, along with rising investment from pharmaceutical and biotechnology companies in drug development and regulatory approvals. Contact centers for pharma enhance clinical trials by managing communication between researchers, participants, and healthcare providers, ensuring timely coordination, patient engagement, query resolution, and accurate information flow throughout all phases of the trial process to improve efficiency and compliance. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the expansion of clinical trials is driving the growth of the contact centers for pharma industry. The growth of specialty and biologic drugs is expected to propel the growth of the contact centers for pharma market going forward. Specialty and biologic drugs refer to advanced, high-complexity therapies derived from living organisms and used to treat chronic, rare, or complex diseases. Specialty and biologic drugs are rising due to rapid advances in biotechnology and an increasing global burden of chronic and complex diseases, which require more targeted and effective treatment options. Contact centers for pharma enable effective management of specialty and biologic drugs through continuous patient engagement, adherence monitoring, education on treatment regimens, coordination between healthcare providers and patients, and timely resolution of therapy-related queries, ensuring proper usage and improved treatment outcomes. For instance, in February 2025, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the 2023 WHO Essential Medicines List includes 81 biologic therapies, representing over 15% of all listed medicines. Therefore, the growth of specialty and biologic drugs is driving the growth of the contact centers for pharma industry. The growth of patient support programs is expected to propel the growth of the contact centers for pharma market going forward. Patient support programs are structured healthcare services provided by pharmaceutical companies to assist patients in accessing, adhering to, and managing prescribed therapies. Patient support programs are rising due to the increasing complexity of therapies, which makes it difficult for patients to manage medication schedules, side effects, and long-term treatment requirements without structured guidance and ongoing support. Patient support programs enhance contact centers for pharma by creating a continuous communication system where patients receive real-time assistance, adherence reminders, and treatment guidance through centralized channels, which increases patient engagement and improves the efficiency and demand for pharma-focused contact center services. For instance, in August 2024, according to the Health Resources and Services Administration (HRSA), a US-based government agency, HRSA-funded health centers served over 31 million patients in 2023, with the majority being low-income individuals and vulnerable populations. Therefore, the growth of patient support programs is driving the growth of the contact centers for pharma industry.

Key Players In The Global Contact Centers For Pharma Market

Major companies operating in the contact centers for pharma market are Accenture plc, Capgemini SE, Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., Infosys BPM Limited, Wipro Limited, HCL Technologies Limited, Teleperformance SE, Concentrix Corporation, Veeva Systems Inc., ICON Public Limited Company, Syneos Health Inc., Genpact Limited, Foundever Group S.A., Genesys Telecommunications Laboratories Inc., NICE Ltd., Conduent Incorporated, ExlService Holdings Inc., WNS (Holdings) Limited, TTEC Holdings Inc., RingCentral Inc., Inizio Engage, EVERSANA, ProPharma Group, Talkdesk Inc., Ubiquity Global Services Inc., Fusion CX Limited, Qualfon Group, IntelePeer Cloud Communications LLC, PharmaCentra LLC

Regional Outlook

North America was the largest region in the contact centers for pharma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Contact Centers For Pharma Market?

The contact centers for pharma market consists of revenues earned by entities by providing services such as multi-channel customer support, medical information services, patient engagement programs, call handling for drug safety reporting, omnichannel communication management, CRM integration, data capture and analytics, and outsourcing of contact center operations for pharmaceutical companies. The market value includes the value of related services and technology platforms used to deliver these services. Only services exchanged between entities or provided to end users are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Contact Centers For Pharma Market Report 2026?

The contact centers for pharma market research report is one of a series of new reports from The Business Research Company that provides contact centers for pharma market statistics, including contact centers for pharma industry global market size, regional shares, competitors with a contact centers for pharma market share, detailed contact centers for pharma market segments, market trends and opportunities, and any further data you may need to thrive in the contact centers for pharma industry. This contact centers for pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.